13F Pro13F Pro

Saturn V Capital Management LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1964437
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare100.0%$697.5M

AUM History

13fpro.ai/research/fund/saturn-v-capital-management-lp-1964437

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/saturn-v-capital-management-lp-1964437

Saturn V Capital Management LP 13F holdings — Q2 2026

$697.5M portfolio (+26.3% QoQ) · 23 holdings · Q2 2026 13F · top 10 are 76% of the stock portfolio

All holdings — Saturn V Capital Management LP (Q2 2026)

23 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
XFOR$XFORX4 Pharmaceuticals, Inc$32.6M+8%
MNPR$MNPRMonopar Therapeutics$28.9M-10%
DYN$DYNDyne Therapeutics, Inc.$23.5M+9%
TRVI$TRVITrevi Therapeutics, Inc.$19.6MNew
ZURA$ZURAZura Bio Ltd$12.4M+184%
SGMT$SGMTSagimet Biosciences Inc.$11.4MNew
OCS$OCSOculis Holding AG$9.5M+33%
IKT$IKTInhibikase Therapeutics, Inc.$7.9M+0.1%
VIR$VIRVir Biotechnology, Inc.$7.9MNew
IVVD$IVVDInvivyd, Inc.$7.3M-23%
ANRO$ANROAlto Neuroscience, Inc.$4.8M+105%
MSLE$MSLESatellos Bioscience Inc.$2.7M—
OVID$OVIDOvid Therapeutics Inc.$1.8M-84%

What changed in Q2 2026

Against the previous quarter's 13F: 3 new, 13 added to, 6 trimmed, 1 sold out. Share-count changes; largest moves by dollar size first.

New positions (3)

  • TRVI$TRVITrevi Therapeutics, Inc.$19.6M

    first bought this quarter

  • SGMT$SGMTSagimet Biosciences Inc.$11.4M

    first bought this quarter

  • VIR$VIRVir Biotechnology, Inc.$7.9M

    first bought this quarter

Added to (13)

  • IMMX$IMMXImmix Biopharma, Inc.+26%

    now $48.0M · held 3 qtrs, 3 adds in a row

  • CELC$CELCCelcuity Inc.+31%

    now $38.7M · held 6+ qtrs

  • ZURA$ZURAZura Bio Ltd+184%

    now $12.4M · held 2 qtrs, 2 adds in a row

  • IRON$IRONDisc Medicine, Inc.+17%

    now $38.4M · held 6+ qtrs, 2 adds in a row

  • AMLX$AMLXAmylyx Pharmaceuticals, Inc.+6%

    now $83.0M · held 6+ qtrs

  • CADL$CADLCandel Therapeutics, Inc.+14%

    now $34.0M · held 2 qtrs, 2 adds in a row

+7 more in the Excel export

Trimmed (6)

  • OVID$OVIDOvid Therapeutics Inc.-84%

    now $1.8M · held 3 qtrs

  • ALMS$ALMSALUMIS INC.-9%

    now $82.0M · held 3 qtrs

  • ABVX$ABVXAbivax S.A.-4%

    now $69.1M · held 6+ qtrs, 3 trims in a row

  • MNPR$MNPRMonopar Therapeutics-10%

    now $28.9M · held 4 qtrs

  • IVVD$IVVDInvivyd, Inc.-23%

    now $7.3M · held 3 qtrs

  • JAZZ$JAZZJazz Pharmaceuticals plc-1%

    now $38.8M · held 5 qtrs, 3 trims in a row

Sold out (1)

  • COGT$COGTCogent Biosciences, Inc.was $24.1M

    held 9+ qtrs

Firm AUM (Form ADV): $793.2M as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Saturn V Capital Management LP has filed, 14 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Saturn V Capital Management?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Saturn V Capital Management's top 20 holdings: 12/100 (our AI quality score, weighted by position size; 5 of the 20 are scored)

Top 10 since filing

-19.7%

Value-weighted move of the 10 largest stock positions

Turnover

8%

Last quarter; 71% over the last 4

Top 10 weight

76%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

60%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 6 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Saturn V Capital Management LP disclosed 23 positions worth $697.5M in its Form 13F-HR for Q2 2026, led by $AMLX (Amylyx Pharmaceuticals, Inc.) at 11.9% of the equity portfolio, followed by $ALMS and $ABVX. During the quarter the fund opened 3 new positions and exited 1 — including a new stake in $TRVI and a full exit from $COGT. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Saturn V Capital Management LP’s Form 13F-HR filing with the SEC under CIK 1964437.

Funds like this

managers whose biggest positions overlap Saturn V Capital Management's
TCG Crossover Management, LLC$4.16B 13F book · 5 shared top holdingsABVXAMLXDYNIRONOctagon Capital Advisors LP$1.11B 13F book · 5 shared top holdingsABVXALMSIRONPHVSIkarian Capital, LLC$928.17M 13F book · 7 shared top holdingsABVXALMSPCVXPHVSCaligan Partners LP$2.13B 13F book · 3 shared top holdingsABVXPCVXSGMTGREAT POINT PARTNERS LLC$529.12M 13F book · 6 shared top holdingsABVXALMSIMMXAMLXRA CAPITAL MANAGEMENT, L.P.$11.51B 13F book · 4 shared top holdingsPCVXIRONABVXMNPR

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Saturn V Capital Management LP

13F Pro is an AI hedge fund tracker and stock research platform. For Saturn V Capital Management LP (SEC CIK: 1964437), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Saturn V Capital Management LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.